Q: What is Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript Summary?
Here are the specific viewpoints from earnings call
Bullish Points:
1. Worldwide sales increased by 3.9%, with a 7.8% growth in the U.S.
2. Operational sales growth excluding the impact of the COVID-19 vaccine was 7.6% worldwide.
3. Net earnings were $5.4 billion, with adjusted net earnings of $6.6 billion, representing increases of 3.8% and 12.4%, respectively.
4. Innovative Medicine sales increased by 2.5%, with key brands and recently launched products delivering double-digit growth.
5. Darzalex growth was 21%, primarily driven by share gains.
6. Carvykti achieved sales of $157 million, driven by capacity expansion and strong demand.
7. Erleada delivered strong growth of 28.4%, primarily driven by share gains.
8. Growth in pulmonary hypertension was driven by favorable patient mix and market growth.
9. Tremfya sales growth of 27.6% was driven by market growth and share gains.
10. MedTech sales increased by 6.3%, with strong performance in various sectors.
Bearish Points:
1. Sales outside of the U.S. declined by 0.3%.
2. Innovative Medicine sales saw a decline of 4% outside of the U.S.
3. Stelara growth was partially offset by unfavorable patient mix in the U.S. and share loss in PsO and PsA.
4. Xarelto was negatively impacted by unfavorable patient mix, expected to continue throughout the year.
5. Imbruvica sales decreased due to competitive pressures.
6. Contact Lenses declined by 2.3%, driven by U.S. stocking dynamics.
7. Elevated payment levels in the first quarter for talc litigation resolution.
8. Anticipated entry of Stelara biosimilars in Europe which may impact sales.
9. Negative foreign currency impact estimated at $700 million for the full year.
10. Expected dilution to adjusted earnings per share in 2024 of approximately $0.10 per share due to financing costs for the acquisition of Shockwave.
For more information about Johnson & Johnson(JNJ)'s earnings call, you can read the relevant news: Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
